ESR1 and breast cancer: This enrichment of immune related gene sets may be indicative of immune cell infiltration in some tumours and suggests that a subset of ER+ breast cancer patients have a robust anti-tumour immune response and that this in turn may be associated with improved survival [39, 44, 45].